New data underscores the comprehensive scope of UK pharmaceutical regulation: 100 percent of medicine brokers operating in the United Kingdom must be registered with the Medicines and Healthcare products Regulatory Agency and appear on its public registry. This universal registration requirement eliminates regulatory gaps in pharmaceutical intermediary oversight, ensuring complete visibility across the supply chain.
The public registry functions as a verification tool enabling healthcare institutions and supply chain partners to authenticate broker credentials before engagement. This transparency mechanism directly addresses the threat of counterfeit medicines infiltrating legitimate distribution networks. By maintaining exhaustive registration records, the MHRA creates accountability throughout the medicine brokering sector. Combined with serialization requirements and good distribution practices, this comprehensive registration framework significantly reduces the risk of compromised pharmaceutical products reaching patients.
Read the full article on GMJ Newsroom.
Was this article helpful?
